Inter relationship of plasma lipid profile parameters with plasma uric acid levels in psoriasis


  • Srinivas S. Department of Dermatology, Subbaiah Institute of Medical Sciences, NH-13, Purle, Shivamogga, Karnataka, India
  • Prashanthkumar Goudappala Department of Biochemistry, Subbaiah Institute of Medical Sciences, NH-13, Purle, Shivamogga, Karnataka, India
  • Kashinath R. T. Department of Research and Development, Subbaiah Institute of Medical Sciences, NH-13, Purle, Shivamogga, Karnataka, India



Psoriasis, Uric acid, Total cholesterol, Triacylglycerol


Background: Psoriasis is a chronic immune mediated skin disease accompanied with disturbances in systemic lipid turnover. Hyperuricemia has been frequently observed as an additional complication in psoriasis. The relationship between the raised plasma lipid parameters and the uric acid levels in psoriasis need to be ascertained. A study was undertaken to assess the possible relationship of plasma lipid parameters with plasma uric acid levels in psoriasis and to relate any such relationship to psoriasis disease severity.

Methods: Non arthritic psoriasis patients were randomly selected and were grouped into mild (Group 1), moderate (Group 2) as well as severe (Group 3) based on their PASI scores. Plasma lipid parameters and uric acid levels were assessed in these patients.

Results: The results show a significant (p<0.001) parallel raise in plasma uric acid levels along with plasma lipid parameters with the severity of disease in these patients.

Conclusions: A plasma uric acid level along with plasma total cholesterol and triacylglycerol levels fetch much information on the severity of psoriasis disease.



Seishima M, Seishima M, Mori S, Noma A. Serum lipid and apolipoprotein levels in patients with psoriasis. Br J Dermatol. 1994;130(6):738-42.

Icen M, Crowson CS, McEvoy MT, Dann FJ, Gabriel SE, Kremers HM. Trends in incidence of adult-onset psoriasis over three decades: a population-based study. J Am Acad Dermatol. 2009;60(3):394-401.

Pietrzak A, Michalak-Stoma A, Chodorowska G, Szepietowski JC. Lipid disturbances in psoriasis: an update. Mediators of inflammation. 2010;2010.

Chibowska M. Role of serum lipid in psoriasis. Przeglad Dermatologiczny.1970.57(2):255-260

Pietrzak A, Toruniowa B, Pietrzak B, Chwaluk J. Lipid profile in psoriatic patients according to sex and age. Przeglad Dermatologiczny. 1994;81(5):441-9.

Pietrzak A, Jastrzębska I, Krasowska D, Chodorowska G, Tabarkiewicz J, Tomasiewicz K, et al. Serum pancreatic lipase [EC 3.1. 1.3] activity, serum lipid profile and peripheral blood dendritic cell populations in normolipidemic males with psoriasis. J Molecular Catalysis B: Enzymatic. 2006;40(3-4):144-54.

Mallbris L, Granath F, Hamsten A, Ståhle M. Psoriasis is associated with lipid abnormalities at the onset of skin disease. J Am Acad Dermatol. 2006;54(4):614-21.

Solak Tekin N, Tekin IO, Barut F, Yilmaz Sipahi E. Accumulation of oxidized low-density lipoprotein in psoriatic skin and changes of plasma lipid levels in psoriatic patients. Mediators Inflammation. 2007;2007.

Farshchian M, Zamanian A, Farshchian M, Monsef AR, Mahjub H. Serum lipid level in Iranian patients with psoriasis. J Eur Acad Dermatol Venereol. 2007;21(6):802-5.

Gisondi P, Tessari G, Conti A, Piaserico S, Schianchi S, Peserico A, et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital‐based case–control study. Br J Dermatol. 2007;157(1):68-73.

Cohen AD, Sherf M, Vidavsky L, Vardy DA, Shapiro J, Meyerovitch J. Association between psoriasis and the metabolic syndrome. Dermatology. 2008;216(2):152-5.

Tam LS, Tomlinson B, Chu TW, Li M, Leung YY, Kwok LW, Li TK, Yu T, Zhu YE, Wong KC, Kun EL. Cardiovascular risk profile of patients with psoriatic arthritis compared to controls—the role of inflammation. Rheumatology. 2008;47(5):718-23.

Ferretti G, Simonetti O, Offidani AM, Messini L, Cinti B, Marshiseppe I, Bossi G, Curatola G. Changes of plasma lipids and erythrocyte membrane fluidity in psoriatic children. Pediatric Res. 1993;33(5):506-09.

Rocha-Pereira P, Santos-Silva A, Rebelo I, Figueiredo A, Quintanilha A, Teixeira F. Dislipidemia and oxidative stress in mild and in severe psoriasis as a risk for cardiovascular disease. Clinica Chimica Acta. 2001;303(1-2):33-9.

Akhyani M, Ehsani AH, Robati RM, Robati AM. The lipid profile in psoriasis: a controlled study. J Eur Acad Dermatol Venereol. 2007;21(10):1330-2.

Javidi Z, Meibodi NT, Nahidi Y. Serum lipids abnormalities and psoriasis. Indian J Dermatol. 2007;52(2):89.

Amin T, Saied E, Abdou SH. Atherosclerotic risk in psoriasis. J Pan-Arab League Dermatologists. 2005;16(2):39-45.

Bajaj DR, Mahesar SM, Devrajani BR, Iqbal MP. Lipid profile in patients with psoriasis presenting at Liaquat University Hospital Hyderabad. JPMA. J Pakistan Med Association. 2009;59(8):512.

Reynoso-von Drateln C, Martínez-Abundis E, Balcázar-Muñoz BR, Bustos-Saldaña R, González-Ortiz M. Lipid profile, insulin secretion, and insulin sensitivity in psoriasis. J Am Acad Dermatol. 2003;48(6):882-5.

Johnson RJ, Kang DH, Feig D, Kivlighn S, Kanellis J, Watanabe S, et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension. 2003;41(6):1183-90.

Carnethon MR, Fortmann SP, Palaniappan L, Duncan BB, Schmidt MI, Chambless LE. Risk factors for progression to incident hyperinsulinemia: the Atherosclerosis Risk in Communities Study, 1987–1998. Am J Epidemiol. 2003;158(11):1058-67.

Nakanishi N, Okamoto M, Yoshida H, Matsuo Y, Suzuki K, Tatara K. Serum uric acid and risk for development of hypertension and impaired fasting glucose or Type II diabetes in Japanese male office workers. Eur J Epidemiol. 2003;18(6):523-30.

Fang J, Alderman MH. Serum uric acid and cardiovascular mortality: the NHANES I epidemiologic follow-up study, 1971-1992. JAMA. 2000;283(18):2404-10.

Prashanthkumar G, Nagendra S, Kashinath RT. Plasma Uric Acid Levels in Relation to Plasma Cholesterol Levels in Type-2 Diabetes Mellitus. Global J Med Res. 2015.

Lea Jr WA, Curtis AC, Bernstein IA. Serum Uric Acid Levels in Psoriasis1. J Investigative Dermatology. 1958;31(5):269-71.

Johnson RJ, Segal MS, Sautin Y, Nakagawa T, Feig DI, Kang DH, et al. Potential role of sugar (fructose) in the epidemic of hypertension, obesity and the metabolic syndrome, diabetes, kidney disease, and cardiovascular disease. Am J Clin Nutr. 2007;86(4):899-906.

Johnson RJ, Titte S, Cade JR, Rideout BA, Oliver WJ. Uric acid, evolution and primitive cultures. InSeminars in nephrology. Elsevier. 2005;25(1):3-8.

Naito HK. In coronary artery disease and disorders of lipid metabolism: Clinical chemistry theory analysis co relations. 4th edition. In: Kaplan LA Peace AJ, Kazmierczak SC, Mosby, eds. St louis USA: 2003: 603.

Tietz NW. Clinical guide to laboratory tests, 3rd edition by Saunders Philadelphia USA), 1995: 610.

Matsuzaki Y, Kawaguchi E, Morita Y, Mashige F, Ohisa S, Nakahara K. Evaluation of two kinds of reagents for direct determination of HDL-cholesterol. J Anal Bio-Sc. 1996;19:419-27.

Tietz NW. Clinical guide to laboratory tests. 3rd edition. Philadelphia, USA: Saunders; 1995: 624.

Kumari A, Gowda H. A clinical study of psoriasis and its association with serum lipid profile. J Evolution Med Dent Sci. 2017;6(23):1898-904.

Piskin S, Gurkok F, Ekuklu G, Senol M. Serum lipid levels in psoriasis. Yonsei Med J. 2003;44(1):24-6.

Örem A, Çimşit G, Değer O, Örem C, Vanizor B. The significance of autoantibodies against oxidatively modified low-density lipoprotein (LDL) in patients with psoriasis. Clinica Chimica Acta. 19995;284(1):81-8.

Kural BV, Örem A, Çimşit G, Yandı YE, Calapoǧlu M. Evaluation of the atherogenic tendency of lipids and lipoprotein content and their relationships with oxidant–antioxidant system in patients with psoriasis. Clinica Chimica Acta. 2003;328(1-2):71-82.

Coimbra S, Oliveira H, Reis F, Belo L, Rocha S, Quintanilha A, Figueiredo A, Teixeira F, Castro E, Rocha-Pereira P, Santos-Silva A. Circulating levels of adiponectin, oxidized LDL and C-reactive protein in Portuguese patients with psoriasis vulgaris, according to body mass index, severity and duration of the disease. J Dermatological Sci. 2009;55(3):202-4.

Im SS, Yousef L, Blaschitz C, Liu JZ, Edwards RA, Young SG, Raffatellu M, Osborne TF. Linking lipid metabolism to the innate immune response in macrophages through sterol regulatory element binding protein-1a. Cell Metabolism. 2011;13(5):540-9.

Chakrabarti R, Engleman EG. Interrelationships between mevalonate metabolism and the mitogenic signaling pathway in T lymphocyte proliferation. J Biological Chem. 1991;266(19):12216-22.

Getz GS, Reardon CA. The mutual interplay of lipid metabolism and the cells of the immune system in relation to atherosclerosis. Clin Lipidol. 2014;9(6):657-71.

Wu X, Muzny DM, Lee CC, Caskey CT. Two independent mutational events in the loss of urate oxidase during hominoid evolution. J Molecular Evolution. 1992;34(1):78-84.

Glantzounis GK, Tsimoyiannis EC, Kappas AM, Galaris DA. Uric acid and oxidative stress. Current Pharmaceutical Design. 2005;11(32):4145-51.

Eisen AZ, Seegmiller JE. Uric acid metabolism in psoriasis. J Clin Investigation. 1961;40(8):1486-94.

Scott JT, Stodell MA. Serum uric acid levels in psoriasis. In: Purine Metabolism in Man-IV. Boston, MA: Springer; 1984: 283-285.

Jain VK, Lal H. C-reactive protein and uric acid levels in patients with psoriasis. Indian J Clin Biochem. 2011;26(3):309-11.

Lambert JR, Wright V. Serum uric acid levels in psoriatic arthritis. Annals Rheumatic Dis. 1977;36(3):264-7.






Original Research Articles